Last 28 quarters of trend data · Healthcare · Medical - Diagnostics & Research
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.17 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.11 | 0.04 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.04 | 0.05 |
| — | +201.9% | +169.7% | -53.1% | -38.8% | -29.6% | -66.3% | -67.6% | -70.6% | -51.4% | -51.6% | -35.4% | -71.8% | |
| P/B Ratio | 0.12 | 0.04 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 |
| — | +228.1% | +225.4% | -38.2% | -18.7% | -3.1% | -54.7% | -57.1% | -62.2% | -37.7% | -39.8% | +6.9% | -53.1% | |
| P/FCF | — | 0.30 | 0.14 | — | — | 0.13 | — | — | — | — | — | — | — |
| — | +132.0% | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | -10.73 | — | -75.98 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Burning Rock Biotech Limited's operating margin was -9.5% in Q4 2025, up 2.7 pp QoQ and up 55.5 pp YoY. Gross margin expanded 10.0% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.7% | 78.0% | 75.1% | 72.8% | 73.2% | 71.0% | 71.4% | 70.4% | 68.2% | 64.5% | 67.4% | 68.7% | 69.3% |
| — | +10.0% | +5.2% | +3.3% | +7.3% | +10.0% | +6.0% | +2.6% | -1.6% | -9.4% | -4.1% | +8.8% | +7.2% | |
| Operating Margin | -10.2% | -9.5% | -12.3% | -7.7% | -11.4% | -65.0% | -30.0% | -82.1% | -100.2% | -137.4% | -140.2% | -92.8% | -132.2% |
| — | +85.3% | +59.1% | +90.6% | +88.6% | +52.7% | +78.6% | +11.6% | +24.3% | +10.1% | +7.6% | +54.3% | +31.8% | |
| Net Margin | -10.3% | -12.2% | -12.7% | -6.5% | -10.1% | -64.5% | -27.8% | -79.7% | -96.8% | -134.0% | -137.2% | -89.7% | -130.0% |
| — | +81.1% | +54.2% | +91.8% | +89.5% | +51.8% | +79.7% | +11.2% | +25.6% | +11.9% | +8.4% | +55.2% | +32.6% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -9.9% | -2.8% | -3.0% | -1.7% | -2.3% | -13.2% | -5.4% | -15.5% | -16.4% | -19.9% | -19.1% | -13.0% | -16.8% |
| — | +78.6% | +44.2% | +89.0% | +85.7% | +33.5% | +71.8% | -18.8% | +2.6% | -13.0% | -12.8% | +23.2% | -12.5% | |
| ROA | -6.5% | -1.9% | -2.0% | -1.2% | -1.6% | -8.7% | -3.6% | -10.8% | -12.0% | -14.7% | -14.0% | -9.6% | -12.3% |
| — | +78.3% | +42.5% | +89.3% | +87.1% | +40.9% | +74.6% | -12.6% | +2.6% | -12.8% | -8.7% | +27.7% | -3.5% | |
| ROIC | -39.1% | -8.4% | -9.0% | -6.4% | -9.8% | -33.7% | -11.5% | -40.1% | -57.4% | -60.6% | -52.5% | -36.4% | -47.3% |
| — | +75.2% | +21.7% | +84.0% | +82.9% | +44.4% | +78.1% | -10.0% | -21.3% | -21.7% | -5.4% | +24.8% | -16.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Burning Rock Biotech Limited's Debt/EBITDA ratio is 4.4x — elevated, raising questions about debt serviceability.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.08 | 0.06 | 0.07 | 0.07 | 0.09 | 0.16 | 0.16 | 0.03 | 0.02 | 0.02 | 0.03 | 0.04 |
| — | -10.6% | -61.2% | -56.4% | +179.4% | +461.7% | +603.5% | +404.6% | -33.2% | -63.4% | -53.3% | -37.9% | -15.3% | |
| Debt / EBITDA | — | 4.44 | — | 28.99 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.99 | 2.99 | 3.14 | 3.22 | 3.02 | 2.92 | 3.04 | 3.11 | 3.29 | 3.36 | 3.28 | 3.09 | 3.18 |
| — | +2.5% | +3.6% | +3.7% | -8.4% | -13.1% | -7.3% | +0.6% | +3.5% | +9.7% | -12.1% | -24.1% | -24.6% | |
| Quick Ratio | 2.76 | 2.76 | 2.91 | 2.97 | 2.76 | 2.71 | 2.78 | 2.85 | 3.05 | 3.09 | 2.98 | 2.80 | 2.86 |
| — | +1.7% | +4.8% | +4.1% | -9.4% | -12.3% | -6.8% | +1.9% | +6.4% | +12.8% | -10.0% | -24.5% | -26.4% | |
| Interest Coverage | -1792.00 | -966.33 | -1102.07 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BNR stock.
Burning Rock Biotech Limited's current P/E is -1.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Burning Rock Biotech Limited's current operating margin is -10.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Burning Rock Biotech Limited's business trajectory between earnings reports.